Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Erdafitinib plus abiraterone or enzalutamide in double negative prostate cancer
NCT03999515Phase 2Terminated
- Sponsor
- University of Washington
- Start
- Apr 2020
- Primary completion
- Jun 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of erdafitinib in prostate cancer (PCa), sponsored by University of Washington. Started Apr 2020; status: terminated.
02
Drugs
erdafitinib
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT03999515.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03999515.